AKY15-HK-301_NEPA Study
A phase 2 trial of Netupitant and palonosetron in Breast cancer, run by Chinese University of Hong Kong, active and no longer recruiting.
Overview
AKY15-HK-301_NEPA Study is a phase 2 interventional study registered as NCT03386617 by Chinese University of Hong Kong, with 55 participants planned, started 2018-02-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: NEPA. Conditions recorded: Breast Cancer.
Linked to the drug Netupitant and palonosetron because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialTreatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
Shares Netupitant and palonosetron, Breast cancer (all types) and the tag pipeline.
- TrialSafety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
Shares Netupitant and palonosetron and the tag pipeline.
- TrialImplementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
Shares Breast cancer (all types) and the tag pipeline.
- TrialCryoablation Versus Lumpectomy in Early-Stage Breast Cancer
Shares Breast cancer (all types) and the tag pipeline.
- TrialPrevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling
Shares Breast cancer (all types) and the tag pipeline.
- TrialComparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study)
Shares Breast cancer (all types) and the tag pipeline.
- TrialDiagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer
Shares Breast cancer (all types) and the tag pipeline.
- Trial[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
Shares Breast cancer (all types) and the tag pipeline.